Efficacy and safety of lenvatinib in patients with recurrent hepatocellular carcinoma after liver transplantation

Efficacy and safety of lenvatinib in patients with recurrent hepatocellular carcinoma after liver transplantation

Abstract Introduction Lenvatinib is approved for the treatment of patients with metastatic or recurrent hepatocellular carcinoma (HCC); however, clinical outcomes of lenvatinib therapy in patients with post‐liver transplantation (LT) HCC recurrence remain unclear. We investigated the efficacy and sa...

Full description

Saved in:
Bibliographic Details
Main Authors: Kyunghye Bang, Andrea Casadei‐Gardini, Changhoon Yoo, Massimo Iavarone, Min‐Hee Ryu, Sook Ryun Park, Hyung‐Don Kim, Young‐In Yoon, Dong‐Hwan Jung, Gil‐Chun Park, Chul‐Soo Ahn, Deok‐Bog Moon, Shin Hwang, Ki‐Hun Kim, Gi‐Won Song, Chiara Mazzarelli, Eleonora Alimenti, Stephen L. Chan, Massimo De Giorgio, Baek‐Yeol Ryoo, Sung‐Gyu Lee
Format: Article
Language:English
Published: Wiley 2023-02-01
Series:Cancer Medicine
Subjects:
Albumin–bilirubin grade
chemotherapy
hepatocellular carcinoma
lenvatinib
liver transplantation
Online Access:https://doi.org/10.1002/cam4.5123
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1002/cam4.5123

Similar Items